Biovaxys Announces Issuance Of Dpx Related Patent From The U.S. Patent And Trademark Office

VANCOUVER, BC, July 23, 2024 - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United States Patent and Trademark Office ("USPTO") has issued BioVaxys U.S. Patent No. 12,042,537. ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™.This Patent was recently allowed in #Japan and is currently pending in the European Union.DPX™ is a proprietary lipid-based delivery pl